We've got a couple of big stories you don't want to miss. Drew Armstrong reports that Bristol Myers and Pfizer received letters from the House Select Committee asking about their clinical trial sites in China. Meanwhile, Amgen can't seem to catch a break with Tavneos, with Nicole DeFeudis writing that the New England Journal of Medicine retracted a paper on the drug's pivotal data.